Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus

Merz Pharmaceuticals

Status and phase: Terminated; Phase 2

Conditions: Multiple Sclerosis; Nystagmus, Congenital; Nystagmus, Acquired

Treatments: Drug: Neramexane mesylate

Study type: Interventional

Funder types: Industry

Identifiers

NCT00799942

MRZ 92579-0738/1

2007-007663-25

Details and patient eligibility

About

The purpose of this study is to investigate the long-term safety, tolerability and efficacy of neramexane mesylate in the treatment of congenital idiopathic nystagmus (CIN). In addition, a subgroup of multiple sclerosis (MS) patients suffering from acquired nystagmus will be included.

Enrollment: 48 estimated patients

Sex: All

Ages: 18 to 81 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients who has succesfully completed the lead-in study MRZ 92579-0707/1

Exclusion criteria

• Occurence of any major treatment-emergent adverse event or condition during the previous protocol (MRZ 92579-0707/1)

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)